AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
21.09
+0.72 (3.53%)
At close: Aug 8, 2025, 4:00 PM
21.45
+0.36 (1.71%)
After-hours: Aug 8, 2025, 7:54 PM EDT
Patterson Companies Revenue
AnaptysBio had revenue of $22.26M in the quarter ending June 30, 2025, with 102.93% growth. This brings the company's revenue in the last twelve months to $123.16M, up 304.17% year-over-year. In the year 2024, AnaptysBio had annual revenue of $91.28M with 432.03% growth.
Revenue (ttm)
$123.16M
Revenue Growth
+304.17%
P/S Ratio
5.07
Revenue / Employee
$905,618
Employees
136
Market Cap
588.78M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ANAB News
- 3 days ago - Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential - Seeking Alpha
- 2 months ago - AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement - Seeking Alpha
- 2 months ago - AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point - Benzinga
- 2 months ago - Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - GlobeNewsWire
- 2 months ago - Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 - GlobeNewsWire
- 3 months ago - Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Anaptys Announces Stock Repurchase Plan - GlobeNewsWire